VERU INC. Revenue, Net (Deprecated 2018-01-31)
VERU INC. (VERU) reported Revenue, Net (Deprecated 2018-01-31) of $5.50 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-14.
Discontinued › Income Statement › Revenue
us-gaap:SalesRevenueNet · last filed 2018-08-14
- VERU INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $5.50M, a 27.53% increase year-over-year.
- VERU INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $2.57M, a 6.96% increase year-over-year.
- VERU INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $2.59M, a 20.25% decline year-over-year.
- VERU INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $3.69M, a 3.63% increase year-over-year.
- VERU INC. revenue, net (deprecated 2018-01-31) for fiscal 2017 was $13.66M, a 38.29% decline from fiscal 2016.
- VERU INC. revenue, net (deprecated 2018-01-31) for fiscal 2016 was $22.13M, a 32.13% decline from fiscal 2015.
- VERU INC. revenue, net (deprecated 2018-01-31) for fiscal 2015 was $32.60M, a 33.13% increase from fiscal 2014.
- VERU INC. revenue, net (deprecated 2018-01-31) for fiscal 2014 was $24.49M, a 22.15% decline from fiscal 2013.
| Period end | Revenue, Net (Deprecated 2018-01-31) 3 month | Revenue, Net (Deprecated 2018-01-31) 6 month | Revenue, Net (Deprecated 2018-01-31) 9 month | Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-06-30 | $5.50M 10-Q · filed 2018-08-14 | $8.07M derived: sum of 2 quarters · filed 2018-08-14 | $10.66M 10-Q · filed 2018-08-14 | $14.35M derived: sum of 4 quarters · filed 2018-08-14 |
| 2018-03-31 | $2.57M 10-Q · filed 2018-05-11 | $5.16M 10-Q · filed 2018-05-11 | $8.85M derived: sum of 3 quarters · filed 2018-05-11 | $13.17M derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-12-31 | $2.59M 10-Q · filed 2018-02-14 | $6.28M derived: sum of 2 quarters · filed 2018-02-14 | $10.59M derived: sum of 3 quarters · filed 2018-08-14 | $13.00M derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-09-30 | $3.69M 10-K · filed 2018-01-02 | $8.01M derived: sum of 2 quarters · filed 2018-08-14 | $10.41M derived: sum of 3 quarters · filed 2018-08-14 | $13.66M 10-K · filed 2018-01-02 |
| 2017-06-30 | $4.31M 10-Q · filed 2018-08-14 | $6.72M derived: sum of 2 quarters · filed 2018-08-14 | $9.96M 10-Q · filed 2018-08-14 | $13.53M derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | $2.41M 10-Q · filed 2018-05-11 | $5.65M 10-Q · filed 2018-05-11 | $9.21M derived: sum of 3 quarters · filed 2018-05-11 | $14.77M derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $3.24M 10-Q · filed 2018-02-14 | $6.81M derived: sum of 2 quarters · filed 2018-02-14 | $12.37M derived: sum of 3 quarters · filed 2018-02-14 | $17.14M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-09-30 | $3.56M 10-K · filed 2018-01-02 | $9.12M derived: sum of 2 quarters · filed 2018-01-02 | $13.90M derived: sum of 3 quarters · filed 2018-01-02 | $22.13M 10-K · filed 2018-01-02 |
| 2016-06-30 | $5.56M 10-K · filed 2018-01-02 | $10.33M derived: sum of 2 quarters · filed 2018-01-02 | $18.56M 10-Q · filed 2017-08-09 | $25.72M derived: sum of 4 quarters · filed 2018-01-02 |
| 2016-03-31 | $4.77M 10-K · filed 2018-01-02 | $13.00M 10-Q · filed 2017-05-10 | $20.16M derived: sum of 3 quarters · filed 2018-01-02 | $27.97M derived: sum of 4 quarters · filed 2018-01-02 |
| 2015-12-31 | $8.23M 10-K · filed 2018-01-02 | $15.39M derived: sum of 2 quarters · filed 2018-01-02 | $23.20M derived: sum of 3 quarters · filed 2018-01-02 | $34.18M derived: sum of 4 quarters · filed 2018-01-02 |
| 2015-09-30 | $7.15M 10-K · filed 2016-12-12 | $14.97M derived: sum of 2 quarters · filed 2016-12-12 | $25.95M derived: sum of 3 quarters · filed 2016-12-12 | $32.60M 10-K · filed 2018-01-02 |
| 2015-06-30 | $7.81M 10-K · filed 2016-12-12 | $18.79M derived: sum of 2 quarters · filed 2016-12-12 | $25.45M 10-Q · filed 2016-07-28 | $31.00M derived: sum of 4 quarters · filed 2016-12-12 |
| 2015-03-31 | $10.98M 10-K · filed 2016-12-12 | $17.64M 10-Q · filed 2016-04-28 | $23.19M derived: sum of 3 quarters · filed 2016-12-12 | $31.09M derived: sum of 4 quarters · filed 2016-12-12 |
| 2014-12-31 | $6.66M 10-K · filed 2016-12-12 | $12.21M derived: sum of 2 quarters · filed 2016-12-12 | $20.11M derived: sum of 3 quarters · filed 2016-12-12 | $24.46M derived: sum of 4 quarters · filed 2016-12-12 |
| 2014-09-30 | $5.55M 10-K · filed 2015-12-02 | $13.45M derived: sum of 2 quarters · filed 2015-12-02 | $17.80M derived: sum of 3 quarters · filed 2015-12-02 | $24.49M 10-K · filed 2016-12-12 |
| 2014-06-30 | $7.90M 10-K · filed 2015-12-02 | $12.25M derived: sum of 2 quarters · filed 2015-12-02 | $18.94M 10-Q · filed 2015-07-30 | $23.73M derived: sum of 4 quarters · filed 2015-12-02 |
| 2014-03-31 | $4.35M 10-K · filed 2015-12-02 | $11.04M 10-Q · filed 2015-04-30 | $15.83M derived: sum of 3 quarters · filed 2015-12-02 | $23.11M derived: sum of 4 quarters · filed 2015-12-02 |
| 2013-12-31 | $6.69M 10-K · filed 2015-12-02 | $11.48M derived: sum of 2 quarters · filed 2015-12-02 | $18.76M derived: sum of 3 quarters · filed 2015-12-02 | $28.24M derived: sum of 4 quarters · filed 2015-12-02 |
| 2013-09-30 | $4.79M 10-K · filed 2014-12-02 | $12.07M derived: sum of 2 quarters · filed 2014-12-02 | $21.55M derived: sum of 3 quarters · filed 2014-12-02 | $31.46M 10-K · filed 2015-12-02 |
| 2013-06-30 | $7.28M 10-K · filed 2014-12-02 | $16.76M derived: sum of 2 quarters · filed 2014-12-02 | $26.67M 10-Q · filed 2014-07-31 | $36.58M derived: sum of 4 quarters · filed 2014-12-02 |
| 2013-03-31 | $9.48M 10-K · filed 2014-12-02 | $19.39M 10-Q · filed 2014-05-01 | $29.30M derived: sum of 3 quarters · filed 2014-12-02 | $37.96M derived: sum of 4 quarters · filed 2014-12-02 |
| 2012-12-31 | $9.91M 10-K · filed 2014-12-02 | $19.82M derived: sum of 2 quarters · filed 2014-12-02 | $28.48M derived: sum of 3 quarters · filed 2014-12-02 | $36.31M derived: sum of 4 quarters · filed 2014-12-02 |
| 2012-09-30 | $9.91M derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-02 | $18.57M derived: sum of 2 quarters · filed 2014-12-02 | $26.40M derived: sum of 3 quarters · filed 2014-12-02 | $35.03M 10-K · filed 2014-12-02 |
| 2012-06-30 | $8.66M 10-Q · filed 2013-08-01 | $16.49M derived: sum of 2 quarters · filed 2013-08-01 | $25.12M 10-Q · filed 2013-08-01 | $32.23M derived: sum of 4 quarters · filed 2013-12-03 |
| 2012-03-31 | $7.83M 10-Q · filed 2013-05-02 | $16.47M 10-Q · filed 2013-05-02 | $23.57M derived: sum of 3 quarters · filed 2013-12-03 | $27.09M derived: sum of 4 quarters · filed 2013-12-03 |
| 2011-12-31 | $8.63M 10-Q · filed 2013-01-30 | $15.74M derived: sum of 2 quarters · filed 2013-12-03 | $19.26M derived: sum of 3 quarters · filed 2013-12-03 | $23.55M derived: sum of 4 quarters · filed 2013-12-03 |
| 2011-09-30 | $7.11M derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-03 | $10.63M derived: sum of 2 quarters · filed 2013-12-03 | $14.91M derived: sum of 3 quarters · filed 2013-12-03 | $18.57M 10-K · filed 2013-12-03 |
| 2011-06-30 | $3.52M 10-Q · filed 2012-07-31 | $7.80M derived: sum of 2 quarters · filed 2012-07-31 | $11.46M 10-Q · filed 2012-07-31 | $19.26M derived: sum of 4 quarters · filed 2012-12-04 |
| 2011-03-31 | $4.29M 10-Q · filed 2012-05-01 | $7.94M 10-Q · filed 2012-05-01 | $15.74M derived: sum of 3 quarters · filed 2012-12-04 | $17.49M derived: sum of 4 quarters · filed 2012-12-04 |
| 2010-12-31 | $3.65M 10-Q · filed 2012-01-31 | $11.45M derived: sum of 2 quarters · filed 2012-12-04 | $13.21M derived: sum of 3 quarters · filed 2012-12-04 | |
| 2010-09-30 | $7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-04 | $9.55M derived: sum of 2 quarters · filed 2012-12-04 | $22.22M 10-K · filed 2012-12-04 | |
| 2010-06-30 | $1.75M 10-Q · filed 2011-08-05 | $14.42M 10-Q · filed 2011-08-05 | ||
| 2009-09-30 | $27.54M 10-K · filed 2011-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |